Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma

M A SPITERI, A B MILLAR, D PAVIA, S W CLARKE

From the Department of Thoracic Medicine, Royal Free Hospital, London

ABSTRACT Subcutaneous adrenaline and terbutaline have been compared in a double blind study of 20 patients with acute severe asthma presenting to an accident and emergency department. Ten patients received adrenaline 0.5 mg (0.5 ml) and 10 terbutaline 0.5 mg (0.5 ml) subcutaneously. Further treatment with nebulised salbutamol (5 mg), hydrocortisone (200 mg), and aminophylline (0.9 mg/kg/hour) was started 15 minutes later. All patients reported a reduction in chest tightness within three minutes of receiving both adrenaline and terbutaline and reported no adverse effects. Mean baseline values of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) did not differ significantly between the adrenaline group (130 l min⁻¹ and 0.83 l) and the terbutaline group (111 l min⁻¹ and 0.63 l). After administration of adrenaline PEF had increased by 21% and FEV1 by 40% five minutes after the injection, and by 35% and 64% at 15 minutes. Terbutaline caused a 23% increase in PEF and a 37% increase in FEV1 at five minutes, and a 40% and 58% increase at 15 minutes. There was no significant difference in PEF, FEV1, heart rate, blood pressure, or pulsus paradoxus between the two groups at any time. Continuous electrocardiographic recording showed no abnormalities in either group. Thus in this study subcutaneous adrenaline (0.5 mg) and terbutaline (0.5 mg) produced effective rapid bronchodilatation without serious side effects.

About 1500 patients continue to die from asthma each year in England and Wales, despite self referral to hospital and intensive conventional treatment. Many factors are responsible for this, but one major problem is that severe attacks may start abruptly, often late at night or in the early morning. Our study was stimulated by the death of two young asthmatic women who were known to be "at risk" and for whom we had taken every precaution. Both had had abrupt attacks of asthma, developing within minutes and not responding to pressurised aerosol bronchodilators. Both died despite urgent hospital admission.

There are few reports supporting the use of self administration of parenteral adrenaline or selective β₂ adrenergic drugs in acute asthmatic attacks. Adrenaline appears to have lost favour because of the fear of adverse effects such as tachycardia, ventricular ectopic beats, hypertension, pulmonary oedema, tremor, sweating, and headaches, and even death. A closer look at these reports shows that most do not cite the original papers and most of the adverse effects quoted stem from early observations of adrenaline in status asthmaticus, when high doses—such as 4–10 mg (4–10 ml of 1:1000)—of adrenaline were given.

We therefore designed a study to compare the efficacy and safety of subcutaneous adrenaline and terbutaline as first line treatment for patients with acute severe attacks of asthma presenting to the accident and emergency department. Permission for the study was obtained from the ethical practice subcommittee, and informed consent was obtained from every patient.

Methods

Patients

Twenty patients aged 16–65 years were enrolled in the study (table 1). The mean (SEM) age for the adrenaline group was 31 (2-8) and for the terbutaline group 34 (4-2) years. Twelve were women (six in each group). All patients had an established history of asthma, for which they were receiving longstanding or intermittent bronchodilator treatment.

Selection criteria

All our patients had to fulfill the following clinical and physiological criteria: tachypnoea at rest (≥ 25
breaths/min), sinus tachycardia (≥110 beats/min), and pulsus paradoxus (≥10 mm Hg). All had symptoms of breathlessness and wheezing, which had increased rapidly and were refractory to increasing use of their normal medication. Patients with cardiovascular or cardiac disease (including hypertension) were excluded. Use of additional inhaled or oral medication did not preclude admission to the trial but full details were recorded.

**TREATMENT BEFORE ADMISSION**

The maintenance treatment of each patient during the week before admission is outlined in Table 1. One patient who had not registered with a general practitioner after moving house was receiving no medication. The other 19 patients had used their pressurised aerosol bronchodilator on average three to four times on their way to hospital; six had used terbutaline (750–1500 μg) and 13 salbutamol (600–800 μg). None of the patients had taken any other additional treatment and none had received nebulised bronchodilators or parenteral therapy before or on arrival at hospital. No patient was being treated with systemic corticosteroids. Sixteen patients were brought to hospital by the emergency ambulance service; four were brought by relatives.

**PROCEDURE**

The initial assessment included measurement of heart rate, blood pressure, pulsus paradoxus, peak expiratory flow (PEF), forced expiratory volume in one second (FEV₁), and forced vital capacity (FVC). Then adrenaline 0.5 mg or terbutaline 0.5 mg was administered double blind from coded ampoules as a slow subcutaneous injection over one minute from an insulin syringe. The patient's electrocardiogram was monitored throughout this time and for the succeeding 45 minutes with an oscilloscope, and a continuous record was obtained on magnetic tape for future analysis. Baseline measurements were repeated five and 15 minutes after the injection. At 15 minutes conventional treatment was started. Each patient was given nebulised salbutamol 5 mg (in 1 ml) diluted in 3 ml normal saline and an intravenous infusion of hydrocortisone 200 mg and aminophylline 0.9 mg/kg/h in 500 ml 5% dextrose over six hours. Measurements were repeated at 30 and 45 minutes. An experienced physician was in attendance throughout each study.

**STATISTICAL ANALYSIS**

Wilcoxon's rank sum test for paired and unpaired data was used and values were considered to be significantly different if p ≤ 0.05.

**Results**

On admission to hospital all patients had a respiratory rate of 25–30 breaths/min, sinus tachycardia of more than 110 beats/min and pulsus paradoxus in excess of 10 mm Hg.

**PULMONARY FUNCTION MEASUREMENTS**

There was no significant difference in mean baseline PEF, FEV₁, or FVC between the two groups (Table 2). There was an increase in PEF, FEV₁, and FVC following both adrenaline and terbutaline five and 15 minutes after injection (Table 2, figure), with no significant difference between drugs. Further improvement in spirometric measurements was seen 30 and 45 minutes after nebulised salbutamol and intravenous aminophylline and hydrocortisone, again with no significant difference between groups.

**CARDIOVASCULAR MEASUREMENTS**

Baseline values of heart rate and blood pressure did not differ significantly between the two groups, nor

---

**Table 1** Details of patients receiving subcutaneous adrenaline or terbutaline

<table>
<thead>
<tr>
<th>Patient No:</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of presentation (h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEF (l min⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenaline group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of presentation (h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEF (l min⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PEF—peak expiratory flow; S—salbutamol; T—terbutaline; B—beclomethasone; A—aminophylline; 0—none.
Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma

Table 2  Pulmonary function, heart rate, and blood pressure (mean (SEM) values) at various points during the study

<table>
<thead>
<tr>
<th></th>
<th>At time of treatment</th>
<th>5</th>
<th>15</th>
<th>30</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adrenaline group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEF (l min⁻¹)</td>
<td>110 (10)</td>
<td>157</td>
<td>174</td>
<td>240</td>
<td>256</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>0.83 (0.19)</td>
<td>1.17</td>
<td>1.35</td>
<td>1.9</td>
<td>2.06</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>1.32 (0.24)</td>
<td>1.80</td>
<td>1.94</td>
<td>2.44</td>
<td>2.71</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>112 (8.2)</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>111</td>
</tr>
<tr>
<td>Blood pressure (mm Hg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>systolic</td>
<td>124 (3.7)</td>
<td>123</td>
<td>119</td>
<td>119</td>
<td>119</td>
</tr>
<tr>
<td>diastolic</td>
<td>82 (2.0)</td>
<td>78</td>
<td>76</td>
<td>74</td>
<td>73</td>
</tr>
<tr>
<td><strong>Terbutaline group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEF (l min⁻¹)</td>
<td>100 (13)</td>
<td>134</td>
<td>153</td>
<td>197</td>
<td>214</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>0.63 (0.05)</td>
<td>0.86</td>
<td>1.0</td>
<td>1.32</td>
<td>1.37</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>1.19 (0.16)</td>
<td>1.57</td>
<td>1.97</td>
<td>2.36</td>
<td>2.56</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>122 (4.4)</td>
<td>120</td>
<td>114</td>
<td>119</td>
<td>116</td>
</tr>
<tr>
<td>Blood pressure (mm Hg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>systolic</td>
<td>124 (2.2)</td>
<td>122</td>
<td>118</td>
<td>120</td>
<td>119</td>
</tr>
<tr>
<td>diastolic</td>
<td>78 (2.6)</td>
<td>83</td>
<td>74</td>
<td>75</td>
<td>74</td>
</tr>
</tbody>
</table>

PEF—peak expiratory flow; FVC—forced vital capacity.

was there any significant increase in either measurement after adrenaline or terbutaline or after conventional treatment (table 2). Mean pulsus paradoxus was 15 mm Hg (range 10–20 mm Hg) at the start of the study period, and this decreased significantly in each group after treatment, with no significant difference between adrenaline and terbutaline. The electrocardiograms showed no abnormalities other than sinus tachycardia on entry and throughout the study period.

Discussion

In 1977 Crompton discussed in detail the difficulties of carrying out clinical trials in patients with severe asthma and the problem of recruiting suitable patients before they had received conventional emergency treatment. We tried to ensure that every patient with acute severe asthma presenting to the accident and emergency department at any time of day would be referred for the study before being given nebulised or intravenous treatment. Placebo control was not included as all our subjects had acute severe asthma that required immediate relief; without a placebo we cannot be sure that all of the response seen after administration of adrenaline and terbutaline was due to the drugs, but the rapid subjective and objective improvement that followed the two drugs suggests that most if not all of the response was produced by the drugs.

We found that 0.5 mg adrenaline given subcutaneously was as effective as 0.5 mg subcutaneous terbutaline, and neither caused side effects in these patients. Subjective relief was noted within a mean time of three minutes from the injection, and this was reflected by improvement in pulmonary function.
measurements at five and 15 minutes. No adverse effects were noted with either drug at any time during the treatment. Less controlled clinical studies, without electrocardiographic monitoring, \textsuperscript{7,16-19} have shown no significant difference in bronchodilatation between parenteral adrenaline and terbutaline, and none has reported appreciable side effects. In this study further bronchodilatation occurred after inhalation of nebulised salbutamol and intravenous infusion of hydrocortisone and aminophylline. This has been observed with combined treatment previously, \textsuperscript{20} but possibly some of the additional improvement reflects the continuing action of subcutaneous adrenaline (maximum effect 30 minutes\textsuperscript{22}) or terbutaline (maximum effect 30–60 minutes\textsuperscript{22}).

Barger and Dale in 1910\textsuperscript{22} initiated the use of subcutaneous adrenaline for patients with acute asthma. Adrenaline may cause bronchodilatation through \(\beta\) adrenoceptor agonism\textsuperscript{23} and via its \(\alpha\) adrenergic action, producing decongestion of the bronchial mucosa.\textsuperscript{24} Adverse reports of anxiety, tremor, hypertension, palpitations, and cardiac arrhythmias and even death\textsuperscript{4-11} have also been attributed to \(\alpha\) and \(\beta\) adrenergic stimulation. Having checked these reports we believe that side effects may have been overemphasised, since they have often been associated with the use of massive doses of adrenaline, fast administration, and inadvertent intravenous injection.\textsuperscript{12} Side effects such as palpitations and tremor with smaller doses (0.5 mg) of the drug have been minimal and have not been considered to be a problem by the patient in view of the quick and complete relief from asthma.\textsuperscript{25,26}

Traditionally, caution is urged in the use of adrenaline or \(\beta\) adrenoceptor agonists in the elderly. When subcutaneous adrenaline 0.5 mg was given to 100 asthmatic patients aged 50–80 years and 25 young asthmatic patients aged 23–37 years widespread electrocardiographic changes were seen in over half the elderly patients but in only one of the young patients. Among the elderly patients 27 had angina, 13 hypertension, and nine cardioglycally.\textsuperscript{27}

Although drugs such as terbutaline and salbutamol are \(\beta\) selective, they are not free of adverse effects—some effects indeed, such as tachycardia and tremor, being similar to those seen with adrenaline.\textsuperscript{17} In some studies heart rate changes with terbutaline have exceeded those that followed adrenaline,\textsuperscript{28} and this was for the same amount of bronchodilatation in one study of asthmatic patients.\textsuperscript{7} Dose-response curves for the two drugs have not, however, been compared and bronchodilator equivalence has not been established.

In conclusion, we found that both adrenaline and terbutaline (0.5 mg) given subcutaneously gave rapid and effective bronchodilatation in patients with acute severe asthma with no important side effects. The response was rapid, occurring within three minutes. Subcutaneous administration of either drug by self-administration may be of value to patients prone to abrupt attacks of asthma. Further work is needed but, on the basis of our results and review of the published reports, we believe that subcutaneous administration of both terbutaline and adrenaline is less hazardous than hitherto believed.

We are grateful to Drs D Wynn-Mackenzie, P Jenkins, and O Corrado for their initial help in the study.

References

6 Bateman JRM, Clarke SW. Sudden death in asthma. \textit{Thorax} 1979;34:40–4.
Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma


Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma.

M A Spiteri, A B Millar, D Pavia and S W Clarke

*Thorax* 1988 43: 19-23
doi: 10.1136/thx.43.1.19

Updated information and services can be found at:
http://thorax.bmj.com/content/43/1/19

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/